A Phase 2a, Prospective, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with Diabetic Macular Edema

Grants and Contracts Details

StatusFinished
Effective start/end date12/15/2112/8/22

Funding

  • Unity Biotechnology Incorporated: $6,474.00